Avelas Biosciences is a clinical-stage oncology company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 helps improve surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries.
Avelas is currently in a Phase II/III registration trial for the use of AVB-620 during breast cancer surgery.
Jun 17, 2019
Avelas Biosciences Selected as a 2019 Showcase Company by MedTech InnovatorRead more
Mar 04, 2019
Avelas Biosciences Grows Management TeamRead more
Dec 04, 2018
Avelas Biosciences Presents Phase II, Period 1 Data in Poster Session at San Antonio Breast Cancer SymposiumRead more